Cipla receives very last popularity of standard model of Sunovion Pharmaceuticals by admin- Wednesday, June 23rd, 2021 03:51:19 PM
Cipla has acquired final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from america Food and Drug Administration (USFDA).
Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated common therapeutic equivalent model of Sunovion Pharmaceuticals Inc.’s Brovana.
Brovana is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for:
Long-term, two times every day (morning and night) administration in the preservation remedy of bronchoconstriction in sufferers with continual obstructive pulmonary disorder (COPD), which includes continual bronchitis and emphysema.
According to IQVIA (IMS Health), Brovana had US sales of about $438M for the 12-month period finishing April 2021.